The University of Southampton
University of Southampton Institutional Repository

Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer

Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer
Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer
BACKGROUND: To evaluate safety and efficacy of ipilimumab combined with standard first-line chemotherapy for patients with extensive stage SCLC.

METHODS: Chemotherapy-naïve extensive stage SCLC patients were treated with carboplatin and etoposide up to six cycles. Ipilimumab 10 mg/kg was given on day 1 of cycles 3-6 and every 12 weeks. Response was assessed by RECIST v1.0 and immune related response criteria (irRC). The primary endpoint was 1-year progression-free survival (PFS) according to RECIST. Secondary endpoints included PFS by irRC (irPFS) and overall survival (OS). Autoantibody serum levels were evaluated and correlated with clinical outcomes.

RESULTS: 42 patients were enrolled between September 2011-April 2014, 39 evaluable for safety and 38 for efficacy. 6/38 patients (15.8% [95% CI: 7.4%-30.4%]) were alive and progression-free at 1-year by RECIST. Median PFS was 6.9 months (95%CI: 5.5-7.9). Median irPFS was 7.3 months (95% CI: 5.5-8.8). Median OS was 17.0 months (95% CI: 7.9-24.3). In patients evaluable for response, 21/29 patients (72.4%) achieved an objective response by RECIST and 28/33 (84.8%) by irRC. All patients experienced at least one adverse event; 35/39 (89.7%) patients developed at least one toxicity ? Grade 3; in 27 (69.2%) this was related to ipilimumab. Five deaths were reported to be related to ipilimumab. The positivity of an autoimmune profile at baseline was associated with improved outcomes and severe neurological toxicity.

CONCLUSION: Ipilimumab in combination with carboplatin and etoposide might benefit a subgroup of patients with advanced SCLC. Autoantibody analysis correlates with treatment benefit and toxicity and warrants further investigation.
1556-0864
1511-1521
Arriola, E.
aee66171-e294-42a5-95cf-feeb699e142f
Wheater, M.
3691c3d8-8589-4693-a0dc-c6a8648cd7df
Galea, I.
66209a2f-f7e6-4d63-afe4-e9299f156f0b
Cross, N.
0316c5e0-fafc-4dc1-8a45-6f6a104bb99b
Maishman, T.
cf4259a4-0eef-4975-9c9d-a2c3d594f989
Hamid, D.
9e13568d-14a1-463f-8bd7-97e6bf02b62c
Stanton, L.
8b827763-d839-4b4b-bbf2-358a84110294
Cave, J.
fa0405c9-9597-43f6-a9f4-b9ec5fb7268f
Geldart, T.
829fdbee-84dd-4825-b5eb-0e6e859ba9ff
Mulatero, C.
565c3421-a483-4bba-a129-af99a228c88b
Potter, V.
4a7c2507-5e1f-4020-abc4-bf73ecf8e08b
Dansen, S.
b9f02428-e60e-4dff-a290-6b9bc13ac1c3
Woll, P.J.
97451233-2512-4b84-bddb-93dbec4db4c8
Griffiths, R.
182e5e39-a441-4969-9748-4788a810a0ad
Nolan, L.
8711336e-dc97-46b4-b2f3-186bca774cc3
Ottensmeier, C.
42b8a398-baac-4843-a3d6-056225675797
Arriola, E.
aee66171-e294-42a5-95cf-feeb699e142f
Wheater, M.
3691c3d8-8589-4693-a0dc-c6a8648cd7df
Galea, I.
66209a2f-f7e6-4d63-afe4-e9299f156f0b
Cross, N.
0316c5e0-fafc-4dc1-8a45-6f6a104bb99b
Maishman, T.
cf4259a4-0eef-4975-9c9d-a2c3d594f989
Hamid, D.
9e13568d-14a1-463f-8bd7-97e6bf02b62c
Stanton, L.
8b827763-d839-4b4b-bbf2-358a84110294
Cave, J.
fa0405c9-9597-43f6-a9f4-b9ec5fb7268f
Geldart, T.
829fdbee-84dd-4825-b5eb-0e6e859ba9ff
Mulatero, C.
565c3421-a483-4bba-a129-af99a228c88b
Potter, V.
4a7c2507-5e1f-4020-abc4-bf73ecf8e08b
Dansen, S.
b9f02428-e60e-4dff-a290-6b9bc13ac1c3
Woll, P.J.
97451233-2512-4b84-bddb-93dbec4db4c8
Griffiths, R.
182e5e39-a441-4969-9748-4788a810a0ad
Nolan, L.
8711336e-dc97-46b4-b2f3-186bca774cc3
Ottensmeier, C.
42b8a398-baac-4843-a3d6-056225675797

Arriola, E., Wheater, M., Galea, I., Cross, N., Maishman, T., Hamid, D., Stanton, L., Cave, J., Geldart, T., Mulatero, C., Potter, V., Dansen, S., Woll, P.J., Griffiths, R., Nolan, L. and Ottensmeier, C. (2016) Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer. Journal of Thoracic Oncology, 11 (9), 1511-1521. (doi:10.1016/j.jtho.2016.05.028). (PMID:27296105)

Record type: Article

Abstract

BACKGROUND: To evaluate safety and efficacy of ipilimumab combined with standard first-line chemotherapy for patients with extensive stage SCLC.

METHODS: Chemotherapy-naïve extensive stage SCLC patients were treated with carboplatin and etoposide up to six cycles. Ipilimumab 10 mg/kg was given on day 1 of cycles 3-6 and every 12 weeks. Response was assessed by RECIST v1.0 and immune related response criteria (irRC). The primary endpoint was 1-year progression-free survival (PFS) according to RECIST. Secondary endpoints included PFS by irRC (irPFS) and overall survival (OS). Autoantibody serum levels were evaluated and correlated with clinical outcomes.

RESULTS: 42 patients were enrolled between September 2011-April 2014, 39 evaluable for safety and 38 for efficacy. 6/38 patients (15.8% [95% CI: 7.4%-30.4%]) were alive and progression-free at 1-year by RECIST. Median PFS was 6.9 months (95%CI: 5.5-7.9). Median irPFS was 7.3 months (95% CI: 5.5-8.8). Median OS was 17.0 months (95% CI: 7.9-24.3). In patients evaluable for response, 21/29 patients (72.4%) achieved an objective response by RECIST and 28/33 (84.8%) by irRC. All patients experienced at least one adverse event; 35/39 (89.7%) patients developed at least one toxicity ? Grade 3; in 27 (69.2%) this was related to ipilimumab. Five deaths were reported to be related to ipilimumab. The positivity of an autoimmune profile at baseline was associated with improved outcomes and severe neurological toxicity.

CONCLUSION: Ipilimumab in combination with carboplatin and etoposide might benefit a subgroup of patients with advanced SCLC. Autoantibody analysis correlates with treatment benefit and toxicity and warrants further investigation.

Text
Accepted Manuscript.pdf - Accepted Manuscript
Download (1MB)

More information

Accepted/In Press date: 23 May 2016
e-pub ahead of print date: 11 June 2016
Published date: September 2016
Organisations: Cancer Sciences, Clinical Trials Unit

Identifiers

Local EPrints ID: 396905
URI: https://eprints.soton.ac.uk/id/eprint/396905
ISSN: 1556-0864
PURE UUID: e1b62bac-d0c9-48f0-91c9-9ada42dd3da5
ORCID for I. Galea: ORCID iD orcid.org/0000-0002-1268-5102
ORCID for L. Stanton: ORCID iD orcid.org/0000-0001-8181-840X

Catalogue record

Date deposited: 16 Jun 2016 14:57
Last modified: 15 Aug 2019 05:26

Export record

Altmetrics

Contributors

Author: E. Arriola
Author: M. Wheater
Author: I. Galea ORCID iD
Author: N. Cross
Author: T. Maishman
Author: D. Hamid
Author: L. Stanton ORCID iD
Author: J. Cave
Author: T. Geldart
Author: C. Mulatero
Author: V. Potter
Author: S. Dansen
Author: P.J. Woll
Author: R. Griffiths
Author: L. Nolan
Author: C. Ottensmeier

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×